OrchestRA and the End of Linear Drug Discovery
Opening — Why this matters now Drug discovery has a reputation problem. It is slow, expensive, and structurally brittle. Despite exponential growth in biomedical data and modeling tools, R&D productivity has declined for decades. The core reason is not lack of intelligence — human or artificial — but fragmentation. Biology, chemistry, and pharmacology still operate like loosely coupled departments passing half-finished work downstream. ...